SGLT2 in Patients With Type 2 Diabetes Lowers Risk of Gout
A retrospective, adjusted analysis of people in China with type 2 diabetes significantly linked SGLT2 inhibitor use with a lower risk of gout compared with those receiving a DPP4 inhibitor. First Look